KRRO

Company Overview — What Does Korro Bio, Inc. Do?

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts. Korro Bio, Inc. (KRRO) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ram Aiyar and employs approximately 70 people. With a market capitalization of $182M, KRRO is one of the notable companies in the Healthcare sector.

Korro Bio, Inc. (KRRO) Stock Rating — Reduce (April 2026)

As of April 2026, Korro Bio, Inc. receives a Reduce rating with a composite score of 20.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.KRRO ranks #3,406 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Korro Bio, Inc. ranks #521 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

KRRO Stock Price and 52-Week Range

Korro Bio, Inc. (KRRO) currently trades at $12.59. The stock lost $0.49 (3.7%) in the most recent trading session. The 52-week high for KRRO is $55.89, which means the stock is currently trading -77.5% from its annual peak. The 52-week low is $5.20, putting the stock 141.9% above its annual trough. Recent trading volume was 34K shares, suggesting relatively thin trading activity.

Is KRRO Overvalued or Undervalued? — Valuation Analysis

Korro Bio, Inc. (KRRO) carries a value factor score of 12/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 3.90x, versus the sector average of 2.75x. The price-to-sales ratio is 39.34x, compared to 1.66x for the average Healthcare stock.

At current multiples, Korro Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Korro Bio, Inc. Profitability — ROE, Margins, and Quality Score

Korro Bio, Inc. (KRRO) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -171.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -77.7% versus the sector average of -33.1%.

On a margin basis, Korro Bio, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -1536.4% (sector: -66.1%). Net profit margin stands at -1446.4%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

KRRO Debt, Balance Sheet, and Financial Health

Korro Bio, Inc. has a debt-to-equity ratio of 121.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 6.90x, indicating strong short-term liquidity. Total debt on the balance sheet is $42M. Cash and equivalents stand at $24M.

KRRO has a beta of 2.16, meaning it is more volatile than the broader market — a $10,000 investment in KRRO would be expected to move 115.6% more than the S&P 500 on any given day. The stability factor score for Korro Bio, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Korro Bio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Korro Bio, Inc. reported revenue of $5M and earnings per share (EPS) of $-12.48. Net income for the quarter was $-88M. Gross margin was 100.0%. Operating income came in at $-95M.

In FY 2025, Korro Bio, Inc. reported revenue of $6M and earnings per share (EPS) of $-12.48. Net income for the quarter was $-117M. Revenue grew 181.5% year-over-year compared to FY 2024. Operating income came in at $-122M.

In Q3 2025, Korro Bio, Inc. reported revenue of $1M and earnings per share (EPS) of $-1.92. Net income for the quarter was $-18M. Operating income came in at $-19M.

In Q2 2025, Korro Bio, Inc. reported revenue of $1M and earnings per share (EPS) of $-2.74. Net income for the quarter was $-26M. Operating income came in at $-27M.

Over the past 8 quarters, Korro Bio, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $5M. Investors analyzing KRRO stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

KRRO Dividend Yield and Income Analysis

Korro Bio, Inc. (KRRO) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

KRRO Momentum and Technical Analysis Profile

Korro Bio, Inc. (KRRO) has a momentum factor score of 25/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 38/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

KRRO vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Korro Bio, Inc. (KRRO) ranks #521 out of 838 stocks based on the Blank Capital composite score. This places KRRO in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing KRRO against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full KRRO vs S&P 500 (SPY) comparison to assess how Korro Bio, Inc. stacks up against the broader market across all factor dimensions.

KRRO Next Earnings Date

No upcoming earnings date has been announced for Korro Bio, Inc. (KRRO) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy KRRO? — Investment Thesis Summary

The quantitative profile for Korro Bio, Inc. suggests caution. The quality score of 14/100 flags below-average profitability. The value score of 12/100 indicates premium valuation. Momentum is weak at 25/100, a headwind for near-term performance. High volatility (stability score 13/100) increases portfolio risk.

In summary, Korro Bio, Inc. (KRRO) earns a Reduce rating with a composite score of 20.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on KRRO stock.

Related Resources for KRRO Investors

Explore more research and tools: KRRO vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare KRRO head-to-head with peers: KRRO vs AZN, KRRO vs SLGL, KRRO vs VMD.